PFG Investments LLC Has $88,000 Stake in Altimmune, Inc. (NASDAQ:ALT)

PFG Investments LLC boosted its position in Altimmune, Inc. (NASDAQ:ALT) by 31.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,500 shares of the company’s stock after buying an additional 4,200 shares during the period. PFG Investments LLC’s holdings in Altimmune were worth $88,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. SBI Securities Co. Ltd. acquired a new position in Altimmune in the fourth quarter valued at $45,000. GAMMA Investing LLC lifted its holdings in Altimmune by 214.2% in the first quarter. GAMMA Investing LLC now owns 6,745 shares of the company’s stock valued at $34,000 after buying an additional 4,598 shares during the period. Virtus ETF Advisers LLC acquired a new position in Altimmune in the fourth quarter valued at $60,000. Cullen Frost Bankers Inc. acquired a new position in Altimmune in the fourth quarter valued at $72,000. Finally, Magnus Financial Group LLC acquired a new position in Altimmune in the first quarter valued at $50,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Trading Down 53.2%

Shares of NASDAQ ALT opened at $3.61 on Friday. The firm’s 50-day moving average price is $5.77 and its 200-day moving average price is $6.15. Altimmune, Inc. has a 1-year low of $2.90 and a 1-year high of $11.16. The firm has a market capitalization of $292.81 million, a P/E ratio of -2.87 and a beta of 0.58.

Altimmune (NASDAQ:ALT) last posted its earnings results on Tuesday, May 13th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.09. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative net margin of 451,200.00% and a negative return on equity of 65.44%. During the same period in the previous year, the firm posted ($0.34) earnings per share. Equities research analysts forecast that Altimmune, Inc. will post -1.35 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on ALT. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a report on Thursday, April 3rd. Wall Street Zen lowered shares of Altimmune from a “hold” rating to a “sell” rating in a report on Saturday, June 14th. Finally, William Blair reiterated a “market perform” rating on shares of Altimmune in a report on Friday, March 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $19.00.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.